Trump Executive Order Tracker

This memorandum directs the Secretary of Health and Human Services to take appropriate action to eliminate waste, fraud, and abuse in Medicaid, including by ensuring Medicaid payments rates are not higher than Medicare.

Orders the Director of the Office of Science and Technology Policy (OSTP Director) to issue guidance for agencies on implementation of “Gold Standard Science” in the conduct and management of their respective scientific activities

This order makes it the policy of the United States to have the most-favored-nation price for prescription drugs and biologics.

This Executive Order establishes a policy of the United States to ensure that federally funded research benefits American citizens without jeopardizing national security, strength or prosperity. The order seeks to strengthen oversight of dangerous gain-of-function research on biological agents and pathogens and other high-risk life science research. It contains the following directives and deadlines.

This order makes it the policy of the United States that Federal health care programs, intellectual property protections, and safety regulations are optimized to provide access to prescription drugs at a lower cost to American patients and taxpayers. 
 
The order directs: (a) the Secretary of Health and Human Services (“Secretary”) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program within 60 days of the order; (b) the Assistant to the President for Domestic Policy, in coordination with the Secretary, the Director of the Office of Management and Budget (OMB Director), and the Assistant to the President for Economic Policy to provide recommendations to the President on how best to stabilize and reduce Medicare Part D premiums within 180 days of the order; and (c) the Secretary to work with Congress to modify the Medicare Drug Price Negotiation Program.
 
The order also contains the following directions and deadlines:

The EO announces a policy of the United States to put patients first and ensure they have the necessary information to make well-informed healthcare decisions. The order builds upon Executive Order 13877 (Improving Price and Quality Transparency in American Healthcare to Put Patients First) of June 24, 2019, and directs Secretary of the Treasury, the Secretary of Labor, and the Secretary of Health and Human Services to take all necessary and appropriate action to implement rapidly and enforce the healthcare price transparency regulations issued pursuant to that order within 90 days. 

This order streamlines the regulation of manufacturing pharmaceutical products and inputs to facilitate the restoration of a robust domestic pharmaceutical manufacturing base.

This order establishes a policy of the federal government to aggressively combat health challenges facing Americans, including mental health, obesity, diabetes, and other chronic diseases. The order establishes the President’s Make America Healthy Again Commission, composed of officials across the federal government, chaired by the Secretary of Health and Human services, and the Assistant to the President for Domestic Policy serving as the Executive Director. 

This order makes it the policy of the Administration to ensure reliable access to IVF treatment, including by easing unnecessary statutory or regulatory burdens to make IVF treatment more affordable. Within 90 days of the order, the Assistant to the President for Domestic Policy will submit to the President a list of policy recommendations on protecting IVF access and aggressively reducing out-of-pocket and health plan costs for IVF treatment.